Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Icagen

Pre-clinical

Pre-clinical

Therapeutic Approach

Restore CFTR Function

This program is working to identify potential therapies for people with CF who have nonsense mutations. Nonsense mutations (also known as “x” or “stop” mutations) in the CFTR gene cause the production of CFTR protein to stop prematurely. Overriding these premature stop signals would allow full-length, functional CFTR protein to be made.

Status

Laboratory studies to develop and test these compounds are underway.

Sponsor

This program is sponsored by Icagen, Inc. and partially funded by the Cystic Fibrosis Foundation.



Contact us about Icagen >